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Table 1
MTHFR Genotype in Healthy Japanese Stratified by Age Groups and Gender
YOUNGER (!55 YEARS) OLDER (55–79 YEARS) OLDEST (x80 YEARS)
n
MTHFR Allelea
n
MTHFR Allelea
n
MTHFR Allelea
/ / or / / / or / / / or /
Maleb 147 .21 .79 227 .15 .85 79 .08 .92
Female 164 .17 .83 259 .13 .87 69 .07 .93
Totalc 311 .19 .81 486 .14 .86 148 .07 .93
a A plus sign () denotes the mutant allele; and a minus sign () denotes the wild-type allele.
b , , for differences among the three age groups.2x  7.25 P  .027
c , , for differences among the three age groups.2x  10.39 P  .006
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The Frequency of the Methylenetetrahydrofolate
Reductase–Gene Mutation Varies with Age in the
Normal Population
To the Editor:
Cardiovascular disease and cerebrovascular disease are
second only to cancer as the leading causes of death in
Japan, and their mortality rates rise with the age of the
population (Health and Welfare Statistics Association
1995). In addition to environmental factors such as
smoking, genetic factors are involved in determining an
individual’s susceptibility to vascular disease. Because
low frequency of genetic risk factors for vascular disease
could contribute to a population’s longevity, the fre-
quency of potentially protective genotypesmay be higher
in the oldest segment of the population.
For the past decade, mild hyperhomocysteinemia has
been recognized as a risk factor for occlusive arterial
disease and thrombosis. Methylenetetrahydrofolate re-
ductase (MTHFR) is the key enzyme in the methylation
of homocysteine. A homozygous mutation of the
MTHFR gene (677CrT; ArV) alters a highly conserved
amino acid, resulting in decreased specific MTHFR ac-
tivity and elevated levels of homocysteine (Frosst et al.
1995). According to a recent report on patients with
premature vascular disease, this mutation is associated
with a threefold increase in risk for premature cardio-
vascular disease (Kluijtmans et al. 1996).
Individuals with the homozygous 677CrT mutation
have been reported to show increased thermolability of
MTHFR (Frosst et al. 1995). One study attributed the
abnormal homocysteine metabolism in 28% of the ho-
mocysteinemic patients with premature vascular disease
to thermolabile MTHFR (Engbersen et al. 1995). An-
other study indicated that an association between the
thermolabile MTHFR defect and coronary artery disease
is independent of other known risk factors for coronary
artery disease (Kang et al. 1993).
These observations led us to speculate that the
MTHFR mutation may be partly responsible for car-
diovascular disease, thus decreasing the probability of
an individual’s reaching old age. To test this hypothesis,
we investigated the frequency of the MTHFR mutation
in 945 unrelated, healthy subjects 14–99 years old, all
Japanese living in a single local area. Information about
health condition (e.g., history of hypertension, hyperlip-
idemia, diabetes mellitus, stroke, and heart disease) was
obtained by semistructured interview of 506 subjects
who were 160 years old. We assessed blood pressure at
rest twice during the interview.
Taking account of the rising rate of mortality due to
cardiovascular and cerebrovascular diseases in people
180 years old, we stratified the subjects into three age
groups: younger (X54 years; ), older (55–79n  311
years; ), and oldest (x80 years; , ofn  486 n  148
whom 22 were x90 years of age). DNA was extracted
from peripheral leukocytes obtained from each subject,
and MTHFR genotyping was performed as described by
Frosst et al. (1995).
As shown in table 1, the MTHFR mutation decreased
as the ages of the subjects increased. The homozygous
MTHFR mutation occurred in 19% of the younger
group and in 14% of the older group, whereas we found
the mutation in only 7% of the oldest group. The ho-
mozygous mutation occurred significantly less often in
both the older and oldest groups than in the younger
group, especially among males (total— , 2df  2 x 
, ; males— , , ;210.39 P  .006 df  2 x  7.25 P  .027
females— , , ). The MTHFR-2df  2 x  3.59 P  .166
genotype distributions for the younger and older age
groups were in Hardy-Weinberg equilibrium, but the dis-
tribution for octogenarians and nonagenarians was not
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Table 2
Frequency of Hypertension History and Mean Blood Pressure at Rest, among MTHFR Genotypes, Stratified by Age Groups
MTHFR ALLELEa
Older Group (55–79 years) Oldest Group (x80 years)
/
( )n  57
/ or /
( )n  333
/
( )n  11
/ or /
( )n  107
No. of individuals with
hypertension:
Present 23 (40.4%) 116 (34.8%) 0b 44 (41.1%)
Absent 34 (59.6%) 217 (65.2%) 11 (100%) 63 (58.9%)
Mean (SD) maximum
blood pressure at rest
(mmHg) 142.5 (35.2) 145.1 (33.4) 147.3 (28.0) 149.9 (30.2)
a A plus sign () denotes the mutant allele; and a minus sign () denotes the wild-type allele.
b , , , with continuity correction.2df  1 x  5.56 P  .018
(i.e., there was a nonsignificant trend, ,2x  4.71 P !
). However, none of the nonagenarians carried the ho-.1
mozygous MTHFR mutation. This finding led us to
compare the frequency of past illness and blood pressure
among subjects of each age group.
As shown in table 2, there were no significant differ-
ences between MTHFR-genotype distribution and the
frequency of any past illness (e.g., hypertension, hyper-
lipidemia, diabetes mellitus, stroke, and heart disease)
among the older group, but among the oldest group the
frequency of hypertension history was lower among sub-
jects with the homozygous MTHFRmutation. Although
this difference was statistically significant according to
the x2 test with continuity correction, this significance
should be interpreted carefully because of the small num-
ber of subjects with the homozygous MTHFRmutation.
Our results suggest that the homozygousMTHFRmu-
tation is a genetic factor that prevents the attainment of
old age. Moreover, it might indicate that persons who
had the homozygousMTHFRmutation, especially those
with high blood pressure, could not attain old age. How-
ever, the finding, among both old age groups, that there
were no blood-pressure differences in subjects with the
homozygous MTHFR mutation versus those with other
genotypes suggests that some other genetic or environ-
mental factors influence longevity. Because folate sup-
plementation lowers homocysteine concentrations in
subjects with hyperhomocysteinemia (Boushey et al.
1995), increased folate intake may promote the longev-
ity of subjects with the homozygous MTHFR mutation.
Further investigation, focusing on this mutation and
other possible risk factors and on their interaction with
other nutritional and genetic factors, as well as the de-
termination of the frequency of the MTHFR mutation
in centenarians, is warranted to clarify the association
between the MTHFR mutation and longevity.
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